Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

NCT00952588 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: AZD1152
DRUG: LDAC

Sponsor

AstraZeneca